Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Read more about Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Read more about Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Read more about Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Immune-related encephalitis after immune checkpoint inhibitor therapy. Read more about Immune-related encephalitis after immune checkpoint inhibitor therapy.
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. Read more about Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Read more about Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Read more about Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series. Read more about Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Read more about HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Read more about Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
